Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Kaohsiung Medical University, Kaohsiung, Taiwan.
Asia Pac J Ophthalmol (Phila). 2021;10(1):87-92. doi: 10.1097/APO.0000000000000352.
Uveitic macular edema is a significant cause of visual impairment in most uveitis types. Treatment options of uveitis have advanced remarkably in recent years. Up to now, corticosteroids remain the mainstay of treatment. Nonsteroidal immunomodulators, and recently the biologic agents, which can reinforce efficacy and enable discontinuation or reduction of steroids to maintenance doses, are becoming increasingly popular in the management of uveitic macular edema. Several medications can be used in intraocular delivery and more and more sustained releasing implants are being developed. This review will briefly focus on the review of local therapy for the management of cystoid macular edema in uveitis, as many of these novel approaches are currently being evaluated in clinical trials.
葡萄膜炎相关性黄斑水肿是大多数葡萄膜炎类型导致视力损害的主要原因。近年来,葡萄膜炎的治疗方法有了显著的进步。到目前为止,皮质类固醇仍然是治疗的主要方法。非甾体类免疫调节剂,以及最近的生物制剂,它们可以增强疗效,并使类固醇能够停药或减少到维持剂量,在葡萄膜炎相关性黄斑水肿的治疗中越来越受欢迎。一些药物可以用于眼内给药,并且越来越多的缓释植入物正在开发中。这篇综述将简要介绍局部治疗葡萄膜炎相关性黄斑水肿的方法,因为目前许多新方法正在临床试验中进行评估。